FGEN Projected Dividend Yield
FibroGen Inc ( NASDAQ : FGEN )FibroGen, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for cancer and anemia. Co.'s pipeline includes Pamrevlumab, a first-in-class antibody targeting connective tissue growth factor (CTGF), in Phase III trials for locally advanced unresectable pancreatic cancer and Phase 2/3 for metastatic pancreatic cancer. Another key product, Roxadustat, is an oral HIF-PH inhibitor that promotes red blood cell production. FibroGen also develops FG-3165 (Anti-Gal9 Antibody) and FG-3175 (Anti-CCR8 Antibody). 21 YEAR PERFORMANCE RESULTS |
FGEN Dividend History Detail FGEN Dividend News FGEN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |